160 related articles for article (PubMed ID: 31406110)
1. The epigenetic factor BORIS (CTCFL) controls the androgen receptor regulatory network in ovarian cancer.
Salgado-Albarrán M; González-Barrios R; Guerra-Calderas L; Alcaraz N; Estefanía Sánchez-Correa T; Castro-Hernández C; Sánchez-Pérez Y; Aréchaga-Ocampo E; García-Carrancá A; Cantú de León D; Herrera LA; Baumbach J; Soto-Reyes E
Oncogenesis; 2019 Aug; 8(8):41. PubMed ID: 31406110
[TBL] [Abstract][Full Text] [Related]
2. The downregulation of putative anticancer target BORIS/CTCFL in an addicted myeloid cancer cell line modulates the expression of multiple protein coding and ncRNA genes.
Teplyakov E; Wu Q; Liu J; Pugacheva EM; Loukinov D; Boukaba A; Lobanenkov V; Strunnikov A
Oncotarget; 2017 Sep; 8(43):73448-73468. PubMed ID: 29088719
[TBL] [Abstract][Full Text] [Related]
3. CTCFL regulates the PI3K-Akt pathway and it is a target for personalized ovarian cancer therapy.
Salgado-Albarrán M; Späth J; González-Barrios R; Baumbach J; Soto-Reyes E
NPJ Syst Biol Appl; 2022 Feb; 8(1):5. PubMed ID: 35132075
[TBL] [Abstract][Full Text] [Related]
4. Targeting CTCFL/BORIS for the immunotherapy of cancer.
Loukinov D
Cancer Immunol Immunother; 2018 Dec; 67(12):1955-1965. PubMed ID: 30390146
[TBL] [Abstract][Full Text] [Related]
5. The cancer-associated CTCFL/BORIS protein targets multiple classes of genomic repeats, with a distinct binding and functional preference for humanoid-specific SVA transposable elements.
Pugacheva EM; Teplyakov E; Wu Q; Li J; Chen C; Meng C; Liu J; Robinson S; Loukinov D; Boukaba A; Hutchins AP; Lobanenkov V; Strunnikov A
Epigenetics Chromatin; 2016; 9(1):35. PubMed ID: 27588042
[TBL] [Abstract][Full Text] [Related]
6. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of BORIS/CTCFL efficiently regulates cancer stemness and metastasis in MYCN amplified neuroblastoma cell line by modulating Wnt/β-catenin signaling pathway.
Garikapati KR; Patel N; Makani VKK; Cilamkoti P; Bhadra U; Bhadra MP
Biochem Biophys Res Commun; 2017 Feb; 484(1):93-99. PubMed ID: 28104398
[TBL] [Abstract][Full Text] [Related]
8. BORIS/CTCFL expression activates the TGFβ signaling cascade and induces Drp1 mediated mitochondrial fission in neuroblastoma.
Makani VKK; Mendonza JJ; Edathara PM; Yerramsetty S; Pal Bhadra M
Free Radic Biol Med; 2021 Nov; 176():62-72. PubMed ID: 34534628
[TBL] [Abstract][Full Text] [Related]
9. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
Alberti L; Losi L; Leyvraz S; Benhattar J
PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
[TBL] [Abstract][Full Text] [Related]
11. Expression of the epigenetic factor BORIS (CTCFL) in the human genome.
de Necochea-Campion R; Ghochikyan A; Josephs SF; Zacharias S; Woods E; Karimi-Busheri F; Alexandrescu DT; Chen CS; Agadjanyan MG; Carrier E
J Transl Med; 2011 Dec; 9():213. PubMed ID: 22168535
[TBL] [Abstract][Full Text] [Related]
12. Molecular Lesions of Insulator CTCF and Its Paralogue CTCFL (BORIS) in Cancer: An Analysis from Published Genomic Studies.
Voutsadakis IA
High Throughput; 2018 Oct; 7(4):. PubMed ID: 30275357
[TBL] [Abstract][Full Text] [Related]
13. Short rare minisatellite variant of BORIS-MS2 is related to bladder cancer susceptibility.
Kim TN; Kim WT; Jeong MS; Mun MH; Kim MH; Lee JZ; Leem SH
Genes Genomics; 2019 Feb; 41(2):249-256. PubMed ID: 30499053
[TBL] [Abstract][Full Text] [Related]
14. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
Zhao Q; Fan C
BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
[TBL] [Abstract][Full Text] [Related]
15. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
Yang M; Xie X; Ding Y
Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
[TBL] [Abstract][Full Text] [Related]
16. BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells.
Debruyne DN; Dries R; Sengupta S; Seruggia D; Gao Y; Sharma B; Huang H; Moreau L; McLane M; Day DS; Marco E; Chen T; Gray NS; Wong KK; Orkin SH; Yuan GC; Young RA; George RE
Nature; 2019 Aug; 572(7771):676-680. PubMed ID: 31391581
[TBL] [Abstract][Full Text] [Related]
17. The Diverging Routes of BORIS and CTCF: An Interactomic and Phylogenomic Analysis.
Jabbari K; Heger P; Sharma R; Wiehe T
Life (Basel); 2018 Jan; 8(1):. PubMed ID: 29385718
[TBL] [Abstract][Full Text] [Related]
18. CTCFL (BORIS) mRNA Expression in a Peripheral Giant Cell Granuloma of the Oral Cavity.
Zambrano-Galván G; Reyes-Romero M; Bologna-Molina R; Almeda-Ojeda OE; Lemus-Rojero O
Case Rep Dent; 2014; 2014():792615. PubMed ID: 25114808
[TBL] [Abstract][Full Text] [Related]
19. CTCF and BORIS in genome regulation and cancer.
Marshall AD; Bailey CG; Rasko JE
Curr Opin Genet Dev; 2014 Feb; 24():8-15. PubMed ID: 24657531
[TBL] [Abstract][Full Text] [Related]
20. Testis-specific transcriptional regulators selectively occupy BORIS-bound CTCF target regions in mouse male germ cells.
Rivero-Hinojosa S; Kang S; Lobanenkov VV; Zentner GE
Sci Rep; 2017 Feb; 7():41279. PubMed ID: 28145452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
